Ophthalmological Microscopes

Welcome to Ophthalmological Microscopes.

Ophthalmological Microscopes Resources

Home > Ophthalmological Microscopes News > Photodynamic Therapy for 101 Early Cancers of the Upper Aerodigestive Tract, the Esophagus, and the Bronchi: A Single-Institution Experience

Photodynamic Therapy for 101 Early Cancers of the Upper Aerodigestive Tract, the Esophagus, and the Bronchi: A Single-Institution Experience

Cancer, when detected at an early stage, has a very good probability of being eradicated by surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates of cure without the side effects of radical therapy. We report on the results of our clinical experience with photodynamic therapy (PDT) for the treatment of early carcinomas in the upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Sixty-four patients with 101 squamous cell carcinomas were treated with three different photosensitizers: hematoporphyrin derivative (HPD), Photofrin II, and tetra (m-hydroxyphenyl)chlorin (mTHPC). Seventy-seven (76%) tumors showed a complete rsponse with no recurrence after a mean follow-up period of 27 months. There was no significant difference in terms of cure rates among the three dyes. However, mTHPC has a stronger phototoxicity and induces a shorter skin photosensitization than either of the other photosensitizers. There were eight major complications: three esophagotracheal fistulae after illumination with red light in the esophagus, two esophageal stenoses following 360° circumferential irradiation, and three bronchial stenoses. Illumination with the less penetrating green light and the use of a 180° or 240° windowed cylindrical light distributor render the risk of complications in the esophagus essentially impossible, without reducing the efficacy of the treatment. Therefore, PDT may be considered as a safe and effective treatment for early carcinomas of the upper aerodigestive tract, the esophagus, and the tracheobronchial tree.

Click Here to read the entire article...

Other Articles:

•	Basilea Pharmaceutica Opens U.S. Phase III Study On Alitretinoin For The Treatment Of Severe Chronic Hand Eczema
	Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that it has opened a clinical phase III study on alitretinoin in the U.S. The "HANDEL" trial (HAND Eczema research of aLitretinoin) is the first ever multi-centered, controlled clinical study for patients with severe chronic hand eczema (CHE) performed in the U.S. "There is a real sense of excitement within the dermatology community with the start of this important trial," said Dr.
	Click Here to read the entire article...

•	Micronova Introduces MicroFiber Fabric for Controlled Environments, Support and General Cleaning
	Micronova Manufacturing launches a MicroFiber fabric option to its existing portfolio of mops, sponges and wipes. This blended polyester material is well suited to cleaning in controlled and support environments as it offers greater absorbency, better friction resistance and cleans more efficiently than traditional cleanroom mop fabrics. The new MicroFiber range of mops hold up to laundering, autoclave and irradiation, and can be considered for single or multi-use applications in biotechnology, hospital and LAR facilities. All mops are designed for use with Micronova’s exclusive line of elec...
	Click Here to read the entire article...

•	Mayor of the "World's Wholesale Capital" Speaks at IESE
	The mayor of one of China's largest cities and a prominent wholesale capital was on IESE's campus recently to describe its model for growth and factors of success.
	Click Here to read the entire article...

•

	Click Here to read the entire article...

•	[Anatomy and Pathology] Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival
	Several isoforms of bFGF were identified in human and transgenic RB and may have implications for tumor growth and chemoresistance.
	Click Here to read the entire article...

•	[Hip] Is prolonged systemic antibiotic treatment essential in two-stage revision hip replacement for chronic Gram-positive infection?
	When using a staged approach to eradicate chronic infection after total hip replacement, systemic delivery of antibiotics after the first stage is often employed for an extended period of typically six weeks together with the use of an in situ antibiotic-eluting polymethylmethacrylate interval spacer. We report our multi-surgeon experience of 43 consecutive patients (44 hips) who received systemic vancomycin for two weeks in combination with a vancomycin- and gentamicin-eluting spacer system in the course of a two-stage revision procedure for deep infection with a median follow-up of 49 months (25 to 83). The antibiotic-eluting articulating spacers fractured in six hips (13.9%) and dislocated in five patients (11.6%). Successful elimination of the infecting organisms occurred in 38 (92.7%) of 41 hips with three patients developing superinfection with a new organism. We conclude that prolonged systemic antibiotic therapy may not be essential in the two-stage treatment of a total hip replacement for Gram-positive infection, provided that a high concentration of antibiotics is delivered locally using an antibiotic-eluting system.
	Click Here to read the entire article...